-
Which BC patients will benefit from metformin?
Primarily people with metabolic syndrome can benefit from including metformin in their BC treatment regimen, according to this article.…
-
Clinical Trial for Metastatic TNBC Now Recruiting
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer Description This phase I trial tests the safety, side effects, and best dose of CF33-hNIS-antiPDL1 in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). CF33-hNIS-antiPDL1 is an…
-
A couple of informative articles on management of ER+ MBC
Some of the esoteric (brain fog at the moment) but useful information are in the detail which lead to chasing down references for more. Nguyen Standard of Care in Hormone Receptor–Positive Metastatic Breast Cancer: Can We Improve the Current Regimens or Develop Better Selection Tools?…
-
Risk of Peritoneal CA post Prophylactic Salpingo-Oophorectomy
https://www.medpagetoday.com/hematologyoncology/ot... The presence of serous tubal intraepithelial carcinoma (STIC) at the time of risk-reducing salpingo-oophorectomy (RRSO) significantly increased the risk of peritoneal carcinomatosis (PC) in BRCA1/2 mutation carriers, a large meta-analysis showed. The risk of PC…
-
Biodegradable gel boosts immune systems attack
https://www.sciencedaily.com/releases/2022/04/2204... A new biodegradable gel improves the immune system's ability to keep cancer at bay after tumors are surgically removed. The gel, tested in mice, releases drugs and special antibodies that simultaneously deplete immune-blocking cells called macrophages from the surgical…
-
RXPonder results
Sorry if this is a repeat but navigating this site is a pain in the tuches/butt! https://www.exactsciences.com/newsroom/rxponder-st... Snippet of info: RxPONDER showed a different effect of chemotherapy based on Recurrence Score® results for postmenopausal and premenopausal women. Postmenopausal women with Recurrence Score…
-
Metformin ....
https://www.sciencedaily.com/releases/2022/02/2202... Computer drug simulations offer warning about promising diabetes and cancer treatment Metformin highly effective in targeting diabetes and some cancers but potentially dangerous with others
-
Molecular Biomarkers Predictive of Resistance to CDK4/6
Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer https://ascopubs.org/doi/10.1200/PO.21.00002 Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have revolutionized the treatment of hormone-positive metastatic breast cancers (mBCs). They are currently…
-
BCO Research: Breast Cancer Patients Use of Cannabis
We're pleased to share with you our new Breastcancer.org Research published in Cancer magazine: Breast Cancer Patients' Use of Cannabis
-
ERBB2-Low Efficacy of CDK 4/6 HR+, ERBB2- BC
ERBB2-Low Expression and Efficacy of CDK 4/6 Inhibitor in HR-Positive, ERBB2-Negative Breast Cancer Kelvin K. H. Bao, MB, BChir, MA1; Leone Sutanto, MB, ChB1; Shirley S. W. Tse, MB, BS1; et al 8-10 minutes November 5, 2021 The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in…
-
Studies recruiting participants
Many of us want to be able to do SOMETHING...ANYTHING.... about this dreadful disease. If we are not practitioners or bench scientists, then communication, advocacy, studies and clinical trails may seem like all we can do ... aside from charitable giving or rendering to direct aid to those in need. So... I am starting this…
-
BC mets in an.models reduced by mdifyng tumor electrical prop.
https://www.sciencedaily.com/releases/2022/01/2201... In normal cells, electrical voltage patterns provide a blueprint for orderly growth. But with cancer, the opposite happens. Marked by a breakdown in the normal electrical patterns generated by the cells, they lose their specialized functions, start expanding into a…
-
Podcast: Top Research Presented at the 2021 SABCS
Top Research Presented at the 2021 San Antonio Breast Cancer Symposium December 21, 2021 Dr. Sara Tolaney is chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women's Cancers at the Dana-Farber Cancer Institute, as well as associate professor of medicine at Harvard Medical…
-
Podcast: Breast Cancer Research at ESMO 2021
Breast Cancer Research at ESMO 2021 October 21, 2021 Dr. Brian Wojciechowski practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and…
-
Racial, Ethnic Minorities Underrepresented in Cancer Research
Racial, Ethnic Minorities Underrepresented in Cancer Research November 12, 2021 Black, Hispanic, American Indian, and Alaskan Native people are vastly underrepresented in research studies on breast, prostate, lung, and colorectal cancer. Read more...
-
Cokie Roberts RIP
Stupid cancer. She was dx in 2002 at age 58 with breast cancer. RIP. 75 years old.
-
Special Report: Increasing Racial Diversity in Clinical Trials
Clinical trials are the main way scientists develop new and improved cancer treatments. Yet less than 5 percent of adults with cancer participate in clinical trials, and most who do are white. Disparities in clinical trial participation among Black women could be one of the reasons they have worse breast cancer outcomes…
-
BCO Revamped Section on Clinical Trials
Clinical trials are carefully designed research studies that depend on human volunteers to improve medical care over time. In cancer research, pre-clinical studies first test new treatments that show promise in the lab or in animals. These treatments may ultimately be tested in clinical trials involving people. Clinical…
-
Podcast: The Importance of Diversity in BC Clinical Trials
The Importance of Diversity in Breast Cancer Clinical Trials September 15, 2021 Dr. Lola Fayanju is the Helen O. Dickens Presidential Associate Professor at the Perelman School of Medicine at the University of Pennsylvania, where she is also chief of breast surgery at Penn Medicine, as well as surgical director of the Rena…
-
Enhertu shows Kadcyla Who’s Boss in HER2+ MBC / DESTINY 03
“Enhertu slashed the risk of disease progression or death by a massive 71.6% over Kadcyla in second-line HER2-positive metastatic breast cancer patients previously treated with Roche's Herceptin and chemo, AstraZeneca and Daiichi reported at the European Society for Medical Oncology 2021 virtual meeting. “The showing is so…
-
Improved survival with Surgery in Metastatic Breast Cancer
Improved Survival With Surgery in Metastatic Breast Cancer | MedPage Today "Selected patients with metastatic breast cancer at diagnosis had significantly better survival with surgery in addition to systemic therapy, an analysis of almost 13,000 patients showed." "Primary Source Annals of Surgical Oncology Source…
-
HER2+ update from OncLive
A recent email from OncLive.com highlights studies and treatments for HER2+ breast cancer, both early and MBC OncLive.com HER2+ Newsletter
-
Seeking a unique treatment for lobular breast cancer
https://www.sciencedaily.com/releases/2021/07/2107... Though the two main histological types of breast cancer -- lobular and ductal -- are treated with the same hormonal therapies, women with lobular breast cancer often have recurrence or metastasis of the disease several years after their initial treatment. In an attempt…
-
Podcast: Breast Cancer Research at the 2021 ASCO Annual Meeting
Breast Cancer Research at the 2021 ASCO Annual Meeting June 28, 2021 Dr. Jennifer Litton is a board-certified medical oncologist and professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, where she is also vice president of clinical research. The 2021 American Society of…
-
revolutionizing cancer therapy
https://www.sciencedaily.com/releases/2021/06/2106... Tel Aviv University's groundbreaking technology may revolutionize the treatment of cancer and a wide range of diseases and medical conditions. In the framework of this study, the researchers were able to create a new method of transporting RNA-based drugs to a…
-
surfaces of silicone breast implants affect the immune system
https://www.sciencedaily.com/releases/2021/06/2106... Every year, about 400,000 people receive silicone breast implants in the United States. According to data from the U.S. Food and Drug Administration, a majority of those implants needs to be replaced within 10 years due to the buildup of scar tissue and other…
-
New findings- improved therapy early-stage, BRCA mut.-assoc. BC
https://www.sciencedaily.com/releases/2021/06/2106... Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a drug that blocks cancer cells from repairing…
-
High Dose Trastuzumab + Pertuzumab for HER2+ Brain Mets
“In the phase II PATRICIA trial reported in the Journal of Clinical Oncology, Nancy U. Lin, MD, and colleagues found that pertuzumab plus high-dose trastuzumab produced central nervous system (CNS) objective responses and clinical benefit in 68% of patients with HER2-positive metastatic breast cancer with progressive brain…
-
Preprint: possible target to overcome Herceptin resistance
Sortilin-related receptor is a druggable therapeutic target in breast cancer “....Identifying alternative HER2-related therapeutic targets could offer means to overcome .... resistance mechanisms. We have previously demonstrated that an endosomal sorting protein, sortilin-related receptor (SorLA), regulates the traffic and…
-
New study: Vaccine for Triple Negative BC
Has anyone heard of this new vaccine, developed by Cleveland Clinic, for triple-negative breast cancer? Key Takeaways * The FDA has approved a triple-negative breast cancer vaccine for use in human clinical trials. * The vaccine was developed by researchers at the Cleveland Clinic in Ohio and works by training the immune…